Objective-Although significant research has detailed angiogenesis during development and cancer, little is known about cardiac angiogenesis, yet it is critical for survival following pathological insult. The transcription factor c-Myc is a target of anticancer therapies because of its mitogenic and proangiogenic induction. In the current study, we investigate its role in cardiac angiogenesis in a cell-dependent and gene-specific context.
V asculogenesis and angiogenesis are critical to the development of physiological and pathological conditions. 1, 2 The adult vasculature is derived from a network of vessels originally created in the embryo through vasculogenesis. During this process, angioblasts proliferate and join to form the primary vascular plexus, which is remodeled by the sprouting and branching of new vessels from preexisting ones; this process is termed angiogenesis. 3 In the normal adult, angiogenesis primarily occurs during the menstrual cycle, placental development and wound healing; however, angiogenesis is induced during pathological conditions, including cardiac hypertrophy, myocardial infarction, and cancer, to expand the vasculature to deliver oxygen and nutrients to newly formed tissue. [4] [5] [6] Without the proper angiogenic response, cardiac hypertrophy can decompensate into heart failure, or tumors can become necrotic and regress. [7] [8] [9] Clearly, a dichotomy of conditions exist; some in which angiogenesis is beneficial and others detrimental.
Many different cell types contribute to cardiac vascular formation, including, but not limited to, the 3 main constituents of the heart: endothelial cells (ECs), fibroblasts, and myocytes. 10 Although ECs provide vascular structure, they also regulate various factors that control blood flow and immune responses. Numerous studies have focused on genetic changes in ECs during angiogenesis, but more recent studies have detailed the importance of other cell types, such as fibroblasts, in the angiogenic process. [11] [12] [13] Specifically, recent studies have begun to uncover an important molecular and mechanical interplay between fibroblasts, myocytes, and ECs during cardiac remodeling and how cell-cell signaling may alter angiogenic potential in the heart. 10, [14] [15] [16] The discovery of common regulators among all of these cell types has the ability to provide a single target to manipulate a complex process.
Induction and manifestation of angiogenesis hinges on the temporal and spatial expression of many different genes originating from the various cell types. 17 The main angiogenic genes, mostly described in development and cancer, include vascular endothelial growth factor and its receptors (Flk-1, Flt-1), angiopoietins, and their common receptor (Tie-2), hypoxia inducible factor-1a, and Ephs/Ephrins. 9, 18 A common link among these genes is their direct or indirect regulation by c-Myc. 19 Previous studies have demonstrated c-Myc's critical role in angiogenesis during development 9, 20, 21 and cancer, 22 ,23 yet its precise role in the heart and individual cellular constituents remains undiscovered despite its gross upregulation and function during cardiac pathology. 24, 25 Moreover, most studies have focused on the effect of c-Myc overexpression on angiogenesis, but the consequences of reduced c-Myc levels remain unknown. Although increased c-Myc levels are able to induce angiogenesis, 26, 27 is c-Myc required for angiogenesis? In addition, what role does c-Myc play in among the individual cell types in the heart, and how does this affect cardiac phenotype? Here, we detail the results of c-Myc loss on the formation and remodeling of the coronary vasculature. Specifically, in vitro and in vivo results demonstrate a cell-specific dependence on c-Myc expression to induce angiogenesis. In addition, we found that genes regulated by c-Myc in cardiac cells were unique when compared to previous studies examining c-Myc target genes in other tissues. 9 Furthermore, in vivo data support the critical role of proper c-Myc expression on physiological vascular formation in the heart during development and throughout cardiac hypertrophy.
Materials and Methods animals
Eight-week-old, male mice with c-Myc floxed (c-myc flox/flox ) alleles were used for cell culture isolation and genotyped for the flox and deleted alleles. 28 Eight-week-old, male c-Myc  mice on a C57BL/63SV129 mixed background were used for associated in vivo studies and screened for the c-Myc null gene. 29 Transverse aortic constriction (TAC) was performed as previously described 30 in 8-week old male c-Myc flox/flox a-MHC-Cre-ER mice described elsewhere. 31 Mice were anesthetized under 3% isoflurane, intubated, the aortic arch visualized, and 6 to 0 silk suture passed under the arch between the innominate and left common carotid arteries. The suture was secured around the aorta and a 28-gauge needle, the needle was removed, chest closed, and mouse extubated. Sham mice underwent identical procedures excluding aortic ligation. Mice were provided buprenorphine via intraperitoneal injection prior to recovery. For day 2 timepoints, mice were injected with tamoxifen (Sigma, MO; intraperitoneal, 0.1 mg/d) for 10 days prior to surgery to delete c-Myc in myocytes before undergoing surgery. For day 28 timepoints, tamoxifen injections began on day 1 after surgery to allow early c-Myc-mediated remodeling processes to occur before gene deletion. Control mice were injected with vehicle or Cre1/ c-Myc 1/1 and Cre-/c-Myc flox/flox mice were injected with tamoxifen. Each control group displayed similar results, and here we report vehicle-treated mice as the control group. All experiments were approved by IACUC and conform to the Guide for the Care and Use of Laboratory Animals.
Cell isolation and tissue Culture
Mouse ventricles were digested with collagenase type I (2 mg/mL; Worthington Biochemicals, NJ) in isolation media (20% FBS in DMEM) for 30 minutes, triturated, and centrifuged. Pellets were incubated with magnetic Dynabeads (Invitrogen, CA) conjugated to a CD31 antibody (BD Pharmingen, CA) and magnetically sorted. The sorted ECs were seeded onto laminin-coated (10 g/mL) tissue culture plates; the negative-sort flow-through was plated onto gelatin-coated plates for differential plating to isolate fibroblasts. ECs were grown in isolation media containing 100 g/mL EC growth supplement (BD Biosciences, CA) 1100 g/mL heparin; fibroblasts were grown in 10% FBS in DMEM. All cells used were between passages 2 to 4.
Gene deletion
Adenoviral Cre-GFP ( Ad-Cre-GFP, Vector Biolabs, PA) was amplified in HEK293A cells and isolated per manufacturer's protocol ( Adeno-X Maxi Purification Kit, Clontech, CA). To delete cmyc, c-myc flox/flox cells were infected with Ad-Cre-GFP to generate knockout (KO) fibroblasts (fibroblasts KO ) and ECs (ECs KO ). For wild-type cells (WT; fibroblasts WT , ECs WT ), we cultured c-myc flox/flox cells with vehicle control or c-myc 1/1 cells with adenoviral Cre, both showing similar results. Following incubation for 48 hours, genomic DNA was isolated using standard PCA cleanup methods and PCR analysis verified deletion of exons 2 and 3 of cmyc in all cells (primer sequences available on request).
tube Formation assay
To assess tube formation in vitro, 200 L/well of Geltrex (Invitrogen, CA) was added to 48-well tissue culture plates and allowed to polymerize for 30 minutes. Cells were added to each culture (8310 5 total; 1:1 ratio for cocultures), and cultures containing leptin had 40 ng/mL of recombinant mouse Leptin protein (Bachem, CA) added to media immediately prior to plating cells on Geltrex. Both WT and KO fibroblasts alone were cultured to verify cell morphology and lack of EC contamination but were not included in subsequent analyses. After 2 or 6 hours, cultures were washed and processed for RNA isolation or fixed in 4% paraformaldehyde and stained with antipan-cadherin (Cell Signaling, MA) and compatible fluorescent secondary antibody (Invitrogen, CA) for image analyses. Light images were taken from 4 separate wells per culture condition using a Nikon Eclipse TS100 microscope with DS-2Mv camera and associated NIS-Elements D software. ImageJ was used to determine tube number, branch points, and tube length. Confocal images were obtained on the Leica TCS SP5 X white Light Laser confocal microscope as 100 m z-stacks. Several cultures were embedded in freezing medium, cryosectioned at 20 m, and stained with hematoxylin and eosin to visualize lumen.
rNa isolation and Microarrays
RNA isolation and purification from left ventricle and septum (N54) or four individual wells per culture condition was performed using the RNeasy Plus Mini Kit (Qiagen, CA). Isolated RNA was quantified and individual samples were reverse transcribed or, for cell culture PCR arrays, evenly combined within each group and reverse transcribed. RT 2 First Strand Kit (Qiagen, CA) was used to produce cDNA according to the manufacturer's protocol. Gene expression was examined using Qiagen RT 2 Profiler Mouse Angiogenesis PCR Arrays and fold change (2 2DDCT ) was used to assess gene expression. Individual samples were analyzed using gene-specific primer pairs and SYBR Green Polymerase (Qiagen, CA) for qPCR reactions to determine sample variability and more accurately assess gene expression (primer sequences available on request).
3-d Collagen Gel assay
Three-D collagen gel cultures were used to observe EC activation and/or tube formation as previously described. 32 To prepare collagen gels, 350 L 5 mg/mL rat tail collagen (Invitrogen, CA), 39 L 103M199 (Invitrogen, CA), 2.1 L 5 N NaOH, and 409 L 13M199 (Invitrogen, CA) were thoroughly mixed and 200 L of cold cell suspension was added for a final concentration of 2310 5 cells/mL. Twenty-eight L of cell-collagen mix was added to 96 half-area well clear flat bottom TC-treated microplates (Corning, NY), polymerized for 30 minutes at 37°C with 5% CO 2 , and then 100 L of indicated conditioned media added. Conditioned media was collected from WT or KO ECs, fibroblasts, or cocultures after 48 hours under normal culture conditions with 10% FBS in DMEM. Three-D cultures were maintained at 37°C with 5% CO 2 for 24 hours, followed by addition of Calcein-AM (Invitrogen, CA) to visualize cells and ensure only live cells were imaged and analyzed. After DAPI counterstaining, gels were fixed in 4% paraformaldehyde and 150 m z-stacks imaged on the Leica TCS SP5 X white Light Laser confocal microscope.
immunohistochemistry
Freshly isolated hearts were snap-frozen in tissue freezing medium and sectioned at 10 m. Immunohistochemical staining was performed via standard procedures described in the DakoCytomation Animal Research Kit (Dako, CA). Briefly, sections were fixed in ice-cold acetone and blocked in 3% H 2 O 2 (excluded for immunofluorescent imaging). Samples were labeled with rat-antimouse CD31 (BD Biosciences, CA) and biotinylated (Dako, CA) or immunofluorescent (Invitrogen, CA) secondary antibody. Biotinylated slides were incubated with Strepavidin-HRP solution and DAB 1HRP (Dako, CA). Samples were visualized using the Dako Chromavision Systems ACIS 3 microscopy system and associated software or the Leica TCS SP5 X white Light Laser confocal microscope for immunofluorescent staining. Total CD31 staining was normalized to nuclei or tissue area to obtain percentage of CD31 staining.
Cardioangiography
Mice were anesthetized with a ketamine/xylazine cocktail and hearts perfused through the left ventricle with saline/heparin followed by fluorescent microspheres (FluroSpheres; Molecular Probes, Invitrogen, CA) into the left ventricle as previously described.33 For c-Myc  mice, 100-m vibratome sections were cut, stained with DAPI to visualize nuclei, and imaged as 42-m z-slices using the Zeiss LSM 510 META confocal microscope. MetaMorph Image analysis software (v6.1) was used for measurements of vessel density (normalized to total nuclei), intercapillary space, and fractal analyses. Day 28 TAC and sham hearts were snap-frozen in tissue freezing medium and sectioned at 10 m, counterstained with DAPI and phalloidin and imaged with the Leica TCS SP5 X white Light Laser confocal microscope. Vessel density measurements (normalized to total nuclei) were analyzed using ImageJ software.
Fractal image analyses
While briefly explained here, we refer to several recent publications for additional information and examples concerning fractal analyses. 33, 34 Vascular beds of murine hearts were initially determined to be fractal objects by applying the box-counting method of determining D, 34 which consists of a grid of boxes of size "e" superimposed over the image of the structure, and the number of boxes containing any part of the structure recorded as "N(e)." The vascular bed of murine cardiac tissue satisfied the conditions of being fractal objects and D b values were determined using HarFA software. 35 The HarFA software assigned mesh sizes of boxes with "e" values ranging from 2 to 179 pixels, and 30 steps within this range were calculated to generate the Log [N(e)] versus Log(1/e) lines to determined D b . In these 403 images, 1 pixel is equal to 0.2287 m.
evans Blue dye assay
Vascular leakage in the heart was measured using Evan's Blue Dye analyses as previously described. 36 Mice were anesthetized using 5% isoflurane and injected intravenously with 100 L of 1% Evans Blue dye via the retro-orbital sinus. Two hours postinjection, animals were anesthetized using a ketamine/xylazine cocktail and hearts perfused with saline/heparin to clear the vasculature. Hearts were harvested and placed into formamide at 37°C for 48 hours. Evans Blue Dye that extravasated into the tissue was then measured using a spectrophotometer at 650 nm. Readings were normalized to heart weights and compared to WT controls.
Western Blotting
Protein was extracted from freshly isolated left ventricular and septal tissue (minimum N54) by homogenization in modified RIPA buffer and quantified. Proteins were separated electrophoretically on 10% polyacrylamide gels and transferred to nitrocellulose membranes. After blocking with 5% BSA, membranes were probed with the following primary antibodies followed by an appropriate HRP-conjugated secondary antibody (BioRad, CA) and chemical development: anti-Angiopoietin 1 (Millipore, MA), anti-Thrombospondin 1 (Santa Cruz, CA), antivascular endothelial growth factor -B (Santa Cruz, CA), anti-Vimentin (Cell Signaling, MA), anti-MMP-2 (Abcam, MA), anti-TGF- (Cell Signaling, MA), and anti-GAPDH (Abcam, MA). The ChemiDoc XRS system (BioRad, CA) and associated software was used to image blots and perform band density measurements.
statistical analyses
Data obtained from tube formation, image analyses, and gene/ protein expression were measured for significance using Student t test or by ANOVA with a Mann-Whitney test. All analyses were performed using Microsoft Excel and Sigma-stat software (SYSTAT Software). 
results in Vitro c-Myc deletion

Loss of c-Myc inhibits in Vitro tube Formation
To accurately and quantitatively measure tube and network formation, cardiac fibroblast and EC cocultures were first seeded onto Geltrex and imaged over a time course in which various stages of angiogenesis were observed ( Figure II in the online-only Data Supplement). These include seeding of cells ( 1 hour), migration (2-3 hours), tube formation (3-6 hours), remodeling (6-10 hours), and degradation ( 10 hours). Tube formation was confirmed by the presence of a lumen in H&E stained sections ( Figure III in the online-only Data Supplement) and peak tube and network formation was observed 6 hours following seeding. As such, this timepoint was used for image capture (Figure 1A-1J ) and measurements were collected for the number of tubes and branch points per field ( Figure 1K ) and average tube length ( Figure 1L ). For experimental groups, cells were seeded onto Geltrex as either single cultures of ECs WT ( Figure 1A) or ECs KO ( Figure 1B ), or cocultures of fibroblasts WT /ECs WT ( Figure 1C ), fibroblasts WT /ECs KO ( Figure 1D ), fibroblasts KO /ECs WT ( Figure 1E ), or fibroblasts KO / ECs KO ( Figure 1F ). In an attempt to enhance tube formation, recombinant murine leptin (a known angiogenic stimulator 37, 38 not found to be regulated by c-Myc, nor detectable in our cultures via Milliplex ® immunoassays) was added to the media of cocultures at the beginning of angiogenesis assays ( Figure 1G-1J ).
Qualitative and quantitative analysis revealed that although ECs WT alone readily formed tubes, ECs KO failed to form significant tube-like structures or networks. Enhancement of the vascular network was observed when ECs WT were cocultured with fibroblasts WT and surprisingly, culturing fibroblasts WT with ECs KO preserved tube formation to the levels observed in fibroblast WT /EC WT cocultures. In addition, average tube length decreased, indicating enhanced remodeling in addition to overall tube formation (Figure 1 ). Fibroblast KO / EC WT cocultures resulted in tube formation similar to ECs WT alone, which is significantly reduced when compared to cocultures containing fibroblast WT . However, remodeling was mostly preserved, as the average tube lengths of fibroblast KO /EC WT cultures did not differ significantly from WT cocultures. Tube formation was further exacerbated when fibroblast KO /EC KO were cocultured, which resulted in similar levels of stagnant tube formation observed in single cultures of ECs KO .
To assess if the lack of tube formation in fibroblast KOcontaining cocultures could be rescued, recombinant murine leptin was added to the cocultures. Indeed, addition of recombinant leptin rescued tube formation and remodeling in fibroblast KO /EC WT and fibroblast KO /EC KO cocultures, with all cocultures displaying similar tube formation and networking ( Figure 1G-1J ), as measured by tube number, branch points, and average tube length ( Figure 1K and 1L). The addition of leptin had no effect on tube formation, branch points, or tube length in fibroblast WT /EC WT or fibroblast WT /EC KO cocultures, most likely due to maximum tube formation occurring on Geltrex regardless of leptin administration.
c-Myc regulates angiogenic Genes during Vascular remodeling
Given the profound morphological changes in vascular formation induced by c-Myc loss and the importance of c-Myc expression in fibroblasts to enhance tube formation in cocultures, we sought to analyze changes in gene expression to uncover potential mechanisms downstream of c-Myc. mRNA was isolated at 2-and 6-hour timepoints after seeding from 4 separate angiogenesis assay wells for each culture condition and analyzed using angiogenesis-specific microarrays. Significant gene changes were considered a 2-fold difference from control levels (fibroblast WT , EC WT , or fibroblast WT /EC WT ), whereas high significance was expression above a 3-fold change. Two hours after seeding, few genes showed significant changes in the experimental groups, and none reached high significance ( Table 1 ). The majority of significant changes in gene expression were observed in fibroblast KO /EC KO cocultures, of which 4 secreted cytokines were upregulated (Csf3, Fgf6, IL-1, and Tnfaip2) and 2 mitogenic cell surface receptors, Bai1 and Fzd5, were downregulated and upregulated, respectively. Interestingly, these changes in gene expression would suggest an increase in angiogenic signaling in KO cocultures; however, just as morphological changes presented clear differences in later stages of angiogenesis, so did gene expression. After 6 hours in culture, 16 genes were markedly changed in 1 or more of the experimental cocultures when compared to fibroblast WT /EC WT cocultures (Table 2) . Additionally, 6 of the 16 altered genes were significantly different (3-fold change), including Col4a3, Cxcl1, F2, IL-1, Lep, and Tnfaip2 (all of which were downregulated except IL-1). The observed changes in secreted factors, extracellular matrix (ECM), and receptor gene expression in KO cocultures supported our morphological data, suggesting decreased angiogenic signaling in fibroblast KO /EC WT and fibroblast KO /EC KO cocultures. Surprisingly, genes previously identified as c-Myc-regulated targets Values are fold regulation up (1) or down (2) and normalized to their wild-type culture counterparts (F WT, EC WT, or F WT1EC WT). F indicates fibroblasts; EC, endothelial cells; WT, wild type; KO, c-Myc knockout. *Indicates significant fold change; †indicates highly significant fold change. Values are fold regulation up (1) or down (2) and normalized to their wild-type culture counterparts (F WT, EC WT, or F WT1EC WT). F indicates fibroblasts; EC, endothelial cells; WT, wild type; KO, c-Myc knockout.
(including Ang-1, Ang-2, MMP-2, MMP-9, and vascular endothelial growth factor) did not display significant changes in expression, which was confirmed by qPCR of individual samples (N54, Figure IV in the online-only Data Supplement). These data indicate that c-Myc has a wide range of direct and/ or indirect target genes and exerts its effect over these genes in a context-dependent manner.
c-Myc is required for angiogenic secreted Factors and direct Cell-Cell interactions
With a majority of genes identified as secreted growth factors, we further investigated the link between these c-Myc-regulated factors and angiogenesis by culturing ECs in a 3-D collagen environment where previous studies have demonstrated that ECs can be activated when stimulated by proangiogenic factors. 32 We cultured ECs WT , ECs KO , fibroblasts WT , fibroblasts KO alone, or cocultured ECs and fibroblasts in 3-D collagen matrices to avoid confounding growth factors present in Geltrex when conditioned media is used to stimulate EC tube formation. Conditioned media collected from ECs WT , fibroblasts WT , and fibroblast WT /EC WT cocultures significantly enhanced EC activation in 3-D cultures when compared to KO conditioned media counterparts in all cultures except for fibroblast WT /EC WT cocultures (Figure 2) , supporting the finding that c-Myc is essential for the secretion of proangiogenic factors. Interestingly, fibroblast WT /EC WT conditioned media did not enhance EC activation above WT single culture conditioned media, indicating that cell-cell interactions do not increase secretion of proangiogenic factors under these tissue culture conditions. Conversely, whereas conditioned media enhanced EC activation in fibroblast KO /EC WT and fibroblast KO / EC KO cocultures, it did not reach the levels of EC activation in fibroblast WT /EC WT cocultures. Taken together, these data indicate that c-Myc is required for normal production of secreted proangiogenic factor. In addition, direct cell-cell interactions that mediate angiogenesis independently of secreted factors also rely on proper c-Myc expression.
reduced c-Myc expression impairs Formation of the Coronary Vasculature in Vivo
To assess the effect of reduced c-Myc expression in vivo, c-myc  mice were used because of the embryonic lethality of c-Myc KO animals. 29 Immunohistochemical analysis revealed significantly less CD31 positive staining in adult c-myc  hearts compared to WT littermates (Figure 3A, 3B , and 3E), indicating reduced cardiac vascularization. To more accurately measure total vascular area and analyze vascular patterning, fluorescent microangiography was performed ( Figure 3C and 3D) , which supported immunohistochemical data by demonstrating a significantly reduced total vascular area in cardiac tissue from c-myc  mice when compared to WT littermates ( Figure 3F ). In addition, we observed a significant decrease in intercapillary space ( Figure 3G ) and an increase in fractal dimensional value (D-value) ( Figure 3H ) in c-myc  hearts. These data indicate dysfunctional and more chaotic vessel patterning in c-myc  hearts, which correlates with the observed in vitro vessel formation defects using cmyc-deficient ECs and fibroblasts. Despite the disruption in vascular networking, vessels maintained normal function, as vascular leak analyses measured by Evan's Blue Dye injection indicated no significant differences between c-myc  and WT hearts ( Figure 3I ).
Cardiomyocyte-specific c-Myc deletion Prevents Vascular remodeling in response to Cardiac Pathology
With c-Myc expression in either ECs or fibroblasts effecting angiogenesis, we next wanted to investigate the effect of c-Myc loss in the third main constituent of the heart, cardiomyocytes. Angiogenesis is a hallmark of cardiac remodeling during pressure overload hypertrophy, while at the same time c-Myc is highly upregulated in myocytes. As such, c-Myc flox/flox a-MHC-Cre-ER mice were subjected to TAC to induce pressure overload and stimulate cardiac remodeling. Prior to surgery, mice were injected with tamoxifen to specifically delete c-Myc in myocytes. Two days after TAC, WT mice displayed a significant decrease in capillary density, representing the initial vascular remodeling period of angiogenesis. However, this effect was abolished in myocyte-specific c-Mycdeficient animals ( Figure 4A-4E) . These data indicate that c-Myc expression in myocytes is essential to early vascular remodeling in response to cardiac stress, an adaptive process required for compensatory cardiac hypertrophy and appropriate remodeling. Subsequently, we investigated the role of c-Myc in angiogenesis after this early remodeling period by conditionally deleting c-Myc in myocytes shortly after TAC surgery (day 4). At 28-days post-TAC, measurements of total vasculature revealed a significant increase in WT TAC hearts ( Figure 4F-4J) . Conversely, myocyte-specific c-Myc-deficient TAC hearts displayed a significantly reduced vascular area, further supporting c-Myc's proangiogenic role in myocytes during the cardiac remodeling process. Taken together, c-Myc expression in myocytes is required for early remodeling events followed by vascular expansion in response to pressure overload.
To evaluate the genes involved in c-Myc-mediated regulation of early angiogenic remodeling events, gene expression changes 2 days after TAC were measured and are illustrated in Tables 3-5 
discussion
Whereas previous studies have illustrated c-Myc's ability to induce angiogenesis in cancer and during embryonic development, the present study illustrates the requirement for c-Myc during coronary angiogenesis. To date, this is the first study to detail the role of c-Myc in coronary angiogenesis and its importance in cell-specific mediated vascular development and remodeling. The discovery that preserved c-Myc expression in fibroblasts can induce angiogenesis in ECs, regardless of their c-Myc expression, sheds light on previous studies that addressed the importance of c-Myc in ECs 20 and induced pluripotent stem cells. 39 We observed that c-Myc has an essential role in vessel formation of ECs cultured alone, but when these cmyc-deficient ECs were cultured with WT fibroblasts angiogenesis was restored. Three-D collagen gel assays using conditioned media indicate that c-Myc mediates angiogenesis through the production of secreted factors in both fibroblasts and ECs, while also controlling cell-cell interactions that directly enhance angiogenesis. In addition, we demonstrate that c-Myc in myocytes is required to initiate vascular remodeling in response to pathological cardiac stress at both early and late stages independently. We also identified a unique set of genes regulated by c-Myc that indicate coordinated interactions among secreted growth factors, immune responses, and ECM remodeling regulate angiogenesis in vitro and in vivo. Consequently, our studies highlight the significance of fibroblasts and myocytes on coronary Cardiac-derived ECs WT alone readily proliferate, migrate, and remodel to form vascular tubes with a lumen when plated on Geltrex. However, deletion of c-Myc in these cells reduces the number of tubes formed by more than half, suggesting that c-Myc expression is critical to tube formation in cardiac ECs. Although these data are contrary to a previous study that found embryonic angiogenic defects were due to c-Myc loss in hematopoietic cells rather than ECs, 20 our coculture data offers an explanation for the observed discrepancy. As expected from previous studies involving ECs and fibroblasts or pericytes, 40, 41 culturing cardiac fibroblasts WT with ECs WT resulted in enhanced angiogenesis, but surprisingly fibroblasts WT and c-Myc-deficient ECs also displayed similar enhanced vascular tube formation and networking. Thus, it is probable that the c-Myc-deficient ECs in the previous study by He et al were enriched by WT fibroblasts in the developing embryo to maintain normal vessel formation. 20 Our data demonstrate that fibroblasts WT are able to sustain tube formation, regardless of EC c-Myc expression. We also observed that c-Myc is fully responsible for the fibroblast-mediated angiogenic enhancement, as fibroblast KO /EC WT cocultures formed vascular tube networks similar to those observed with ECs WT alone. Similarly, fibroblast KO /EC KO cocultures demonstrated stagnant vessel formation, similar to that observed using ECs KO alone. These data conclusively demonstrate that c-Myc is critical for angiogenesis when ECs are separate from fibroblasts, and angiogenic enhancement from fibroblasts is dependent on c-Myc expression. These conclusions infer that, in an in vivo setting where fibroblasts (E and F) , in addition to an increase in intercapillary space (G), and fractal dimensional value (H), indicating a decreased vasculature that is more disorganized in c-myc  hearts. Despite these changes, the vasculature is fully functional, with vascular leak, as measured by Evan's Blue Dye assay, similar in c-myc  and WT hearts (I). For immunostaining, brown is CD31 1 staining and blue demarks nuclei; scale bar represents 20 m; minimum n53; *P0.005. For microsphere-injected hearts, red is microsphere-perfused vasculature and blue is DAPI-stained nuclei; scale bar represents 50 m; minimum n54; *P0.005. KO indicates c-Myc knockout; F, fibroblast; EC, endothelial cell. and ECs are within the same microenvironment, normal c-Myc expression is more critical in fibroblasts rather than ECs to support proper vessel formation. This conclusion also explains observations by Martinez-Fernandez and colleagues where induced pluripotent stem cells only differentiated into cardiomyocytes without c-Myc overexpression in vitro, but in vivo c-Myc expression did not affect overall induced pluripotent stem cells incorporation into the embryo. 39 Again, in the in vivo setting with a heterogeneous mix of cell types, various factors (possibly influenced by c-Myc regulation) are expressed and initiate cell-cell communication to guide differentiation and function. This observation is particularly important when applied to pathological cardiovascular conditions. For example, during cardiac hypertrophy it is well-established that with cardiac growth an increase in vasculature is required to maintain normal function. 42 Our results demonstrate the importance of c-Myc expression in fibroblasts and ECs to induce the required angiogenesis but, given the role of myocytes during the pathological remodeling process, we examined the effect of c-Myc loss in myocytes during cardiac hypertrophy. In fact, the extensive early and late remodeling observed in WT mice (indicated by early vessel regression, followed by an increase in vascular density) was abolished in mice lacking . Quantification of vasculature in wild-type and myocyte-specific conditional c-myc-deficient hearts subjected to transverse aortic constriction (TAC) surgery. Representative images of wild-type (WT) sham (A) and TAC (C) and myocyte-specific c-myc-deficient sham (B) and TAC (D) hearts immunofluorescently stained for CD31 2 days after surgery to identify changes in vascular density. Quantification (E) revealed a significant decrease in vasculature 2 days after TAC in WT hearts, representing the early remodeling and vascular regression phase of angiogenesis. However, this remodeling is abolished in myocyte-specific c-myc-deficient hearts, indicating abnormal angiogenic remodeling in response to cardiac stress. Representative images of WT sham (F) and TAC (G) and myocyte-specific c-myc-deficient sham (H) and TAC (I) hearts with fluorescent microsphere-filled vasculature 28 days after surgery and subsequent quantification (J). Although WT TAC hearts have significantly more vascular area by day 28, myocyte-specific c-myc-deficient TAC hearts have reduced vascular density. Injection of tamoxifen (TAM) induces myocyte-specific c-myc deletion. SHAM indicates sham surgery. Red is CD31 stained vasculature (day 2; A-D) or fluorescent microsphere-filled vasculature (day 28; F-I), green is F-actin marked by phalloidin and blue is DAPI-stained nuclei; scale bar represents 50 m; minimum n54; *5P0.01. c-Myc in myocytes. Although c-Myc expression in these cells is critical in response to pathological insult, the integrity of the vascular microenvironment must be maintained in order to preserve myocyte-EC and fibroblast-EC communication. It is possible that an increase in c-Myc-expressing myocyte, fibroblast or fibroblast-like (eg, pericyte) cell populations would enhance EC vascular formation; however, excessive ECM deposition or morphological changes in these cell populations may interfere with cell-cell signaling, thus preventing angiogenesis.
As a result, we aimed to detail the role of c-Myc in angiogenesis to pinpoint pathways for intervention. Collagen gel assays with conditioned media clarified c-Myc as a regulator of secreted factors in fibroblasts and ECs; both to a similar extent. Although significant, secreted factors only explain a portion of the c-Myc-mediated angiogenic enhancement, indicating that direct cell-cell and cell-ECM interactions are also controlled by c-Myc. These conclusions are supported by the in vitro and in vivo gene analysis and, with c-Myc's profound effect on angiogenic gene expression in cancer model systems, 23, 27 we were interested in establishing an expression pattern in cardiac cells. Gene expression data suggests that the majority of c-Myc-regulated genes are secreted factors, ECM regulatory genes, or immune factors that alter cell adhesion. Surprisingly, angiogenic genes previously found to be regulated by c-Myc overexpression remained unchanged in c-Myc conditional KO hearts in response to early pathological stress or any of the in vitro KO cultures. This suggests a unique, c-Myc-mediated angiogenic gene response in cardiac tissue and/or response to c-Myc loss versus overexpression.
In addition, we examined in vitro timepoints with 2 distinct stages of angiogenesis; the first being migration and the second tube formation and remodeling (although it is noted that migration is an ongoing process throughout angiogenesis). Interestingly, c-Myc loss had a much greater effect on target genes during tube formation and remodeling in vitro. Not only were twice the number of genes significantly regulated when compared to the migration phase, but the regulated genes also displayed greater differences when compared to WT controls. These findings support the in vivo conclusion that c-Myc appears to play a significant role in the tube formation and remodeling stages of angiogenesis.
Further in vivo observations support a role for c-Myc in angiogenesis during developmental stages. Because c-Myc-deficient embryos are lethal before the heart is fully developed, 9, 29 we used c-Myc heterozygotes to assess the effect of diminished c-Myc expression on the developed coronary vasculature, as previous studies had established an effect of cmyc haploinsufficiency on tumor angiogenesis. 23 Comparable to in vitro results, c-myc  mice displayed a significant decrease in coronary vasculature and disorganized vascular patterning when compared to WT littermates. Despite these deficiencies, capillaries remained structurally intact, as vascular leakage remained unchanged. These results also support the relative importance of c-Myc expression in fibroblasts, myocytes, and ECs. Although diminished c-Myc expression in ECs may not affect overall capillary structure, the proliferation rate and guidance by fibroblasts and myocytes may be disrupted due to decreased fibroblast and myocyte c-Myc expression.
Our results provide sufficient groundwork for future studies to examine pathways for intervention to enhance angiogenesis Values are fold regulation up (1) or down (2) . WT, wild type; KO, myocytespecific conditional c-Myc knockout; TAC, transverse aortic constriction surgery; SHAM, sham surgery; IL, interleukin.
*Indicates P0.05.
during cardiac pathology. For example, the most beneficial pathways to focus on are secreted factors from fibroblasts (eg, ECM-modifying and growth factors) and myocytes (eg, cytokine and growth factors). By enhancing these pathways, possibly via c-Myc overexpression, angiogenesis can be enhanced without altering EC expression. c-Myc is overexpressed during cardiac pathology, but more so early during compensated hypertrophy and less during decompensation to heart failure. If c-Myc can be safely expressed in myocytes and/ or fibroblasts without initiating unperturbed cell growth and proliferation, it may enhance angiogenesis and prevent heart failure. In addition, the other, less common cell types of the heart, including pericytes and immune cells, should be investigated in future studies to reveal additional levels of control in the regulation of angiogenesis. An important, overarching aspect of these studies is the origin of cells and the evidence that cardiac-specific vascular changes are manifested differently from cancer or developmental origins. Future in vitro studies focusing on angiogenesis or other gross morphological changes should take this effect into account to accurately portray in vivo models. With heart failure as the number 1 cause of death, it is critical to establish an origin and develop an effective treatment, both of which may lie within the same process: angiogenesis.
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